Vendor, Raritan, NJ, part of Johnson & Johnson
Janssen Pharmaceuticals, Inc.
UEI RDJSZL3THV47, CAGE 78CR4
2 awards and -$392,446,395 obligated between August 8, 2024 and April 20, 2026, 100% under full and open competition, against 1.0 offers on average where reported.
Sells to
Awarding agencies by dollars.
| Office of Assistant Secretary for Preparedness and Response | -$392,446,395 |
Industries
NAICS on the awards, by dollars.
| Professional, Scientific, and Technical ServicesNAICS 541711 | -$392,446,395 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 2 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| HHSO100201500014CApril 20, 2026, Full and Open Competition, 1 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | De-Obligation and Closeout of the Contract in Its Entirety.NAICS 541711, PSC AN11 | -$50,819,834 |
| HHSO100201700018CAugust 8, 2024, Full and Open Competition, 1 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | Janssen Influenza Portfolio and Other Emerging Pathogens Development CandidatesNAICS 541711, PSC 6505 | -$341,626,561 |
- Product and service codes
- AN11 Health R&D Services; Health Care Services; Basic Research6505 Drugs and Biologicals
- Transactions
- 3 across 2 awards